Skip to main content
. Author manuscript; available in PMC: 2019 Sep 30.
Published in final edited form as: Eur J Pharmacol. 2019 Jan 25;848:131–139. doi: 10.1016/j.ejphar.2019.01.037

Fig. 4.

Fig. 4.

5-HT2C receptor agonist efficacy—but not potency—at either IP or β-arrestin pathways significantly correlates with 5-HT2C agonist-induced receptor desensitization of the IP pathway. A. IP production Emax; B. β-arrestin recruitment Emax; C. IP production pEC50; D. β-arrestin recruitment pEC50.